Strahlentherapie und Onkologie

, Volume 189, Issue 2, pp 137–141

Endocrine and visual function after fractionated stereotactic radiotherapy of perioptic tumors

  • M. Kocher
  • H. Treuer
  • M. Hoevels
  • R. Semrau
  • V. Sturm
  • R.-P. Mueller
Original article

Abstract

Purpose

To find out whether the use of stereotactic techniques for fractionated radiotherapy reduces toxicity to the endocrine and visual system in patients with benign perioptic tumors.

Patients and methods

From 1993 to 2009,  29 patients were treated with fractionated stereotactic radiotherapy. The most frequent tumor types were grade I meningioma (n= 11) and pituitary adenoma (n= 10, 7 nonfunctioning, 3 growth hormone-producing). Patients were immobilized with the GTC frame (Radionics, USA) and the planning target volume (PTV; median 24.7, 4.6–58.6 ml) was irradiated with a total dose of 52.2 Gy (range, 45.0–55.8 Gy) in 1.8-Gy fractions using a linear accelerator (6 MeV photons) equipped with a micro-multileaf collimator. Maximum doses to the optic system and pituitary gland were 53.4 Gy (range, 11.5–57.6 Gy) and 53.6 Gy (range, 12.0–57.9 Gy).

Results

Median follow-up was 45 months (range, 10–105 months). Local control was achieved in all but 1 patient (actuarial rate 92% at 5 years and 10 years). In 9 of 29 patients (31%), partial remission was observed (actuarial response rate 40% at 5 years and 10 years). In 4 of 26 patients (15%) with at least partial pituitary function, new hormonal deficits developed (actuarial rate 21% at 5 years and 10 years). This rate was significantly higher in patients treated for a larger PTV (< /> 25 ml: 0% vs. 42% at 5 years and 10 years, p = 0.028). Visual function improved in 4 of 15 patients (27%) who had prior impairment. None of the patients developed treatment-related optic neuropathy, but 2 patients experienced new disease-related visual deficits.

Conclusion

Fractionated stereotactic radiotherapy for benign tumors of the perioptic and sellar region results in satisfactory response and local control rates and does not affect the visual system. The assumption that patients can be spared hypophyseal insufficiency only holds for small tumors.

Keywords

Fractionated stereotactic radiotherapy Benign brain tumors Skull base Optic neuropathy Pituitary insufficiency 

Endokrine und visuelle Funktion nach fraktionierter stereotaktischer Strahlenbehandlung perioptischer Tumoren

Zusammenfassung

Ziel

Zu untersuchen, ob die Anwendung stereotaktischer Techniken bei der fraktionierten Bestrahlung die endokrine und visuelle Toxizität bei der Behandlung von benignenTumoren in der Nähe des optischen Systems reduziert.

Patienten und Methoden

Von1993 bis 2009 wurden n = 29 Patienten (Pat.) behandelt (überwiegend Meningeome Grad I, n = 11, und Hypophysenadenome, n = 10, 7 inaktiv, 3 STH-produzierend). Zur Immobilisierung wurde der GTC-Stereotaxierahmen (Radionics, USA) verwendet. Die Bestrahlung erfolgte an einem Linearbeschleuniger (6 MeV) mit einem motorischen Mikromultileaf-Kollimator. Das Planungs-Zielvolumen (PTV; Median: 24,7 ml, 4,6–58,6 ml) wurde mit einer Gesamtdosis von 52,2 Gy (45,0–55,8 Gy) in Fraktionen von 1,8 Gy bestrahlt. Die Maximaldosis betrug im optischen System 53,4 Gy (11,5–57,6 Gy) und an der Hypophyse 53,6 Gy (12,0–57,9 Gy).

Ergebnisse

Mit einem medianen Follow-up von 45 (10–105) Monaten lag die lokale Kontrollrate nach 5 und 10 Jahren bei 92%. Bei 9/29 (31%) Pat. kam es zu einer partiellen Remission (aktuarisch 40% nach 5 und 10 Jahren). Bei den Pat. mit einer erhaltenen Restfunktion der Hypophyse traten in 15% der Fälle (4/26) neue endokrinologische Ausfälle auf (aktuarisch 21% nach 5 und 10 Jahren), diese Rate war signifikant abhängig von der Größe des PTV (< /> 25 ml: 0% vs. 42% nach 5 Jahren und 10 Jahren, p = 0,028). Die visuelle Funktion verbesserte sich bei 4/15 Pat. (27%) mit vorbestehenden Ausfällen. Kein Pat. entwickelte eine Optikusneuropathie, aber bei 2 Pat. trat eine krankheitsbedingte Sehverschlechterung ein.

Schlussfolgerung

Die stereotaktische fraktionierte Strahlenbehandlung von benignen Tumoren in der Nähe von Sella und optischem System führt zu guten Ansprech- und Kontrollraten und beeinträchtigt das visuelle System nicht. Eine therapiebedingte Hypophysenvorderlappeninsuffizienz kann aber nur bei kleinen Tumoren weitgehend vermieden werden.

Schlüsselwörter

Fraktionierte stereotaktische Strahlentherapie Gutartige Hirntumoren Schädelbasis Optikusneuropathie Hypophyseninsuffizienz 

References

  1. 1.
    Voges J, Kocher M, Runge M et al (2006) Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. Cancer 107:1355–1364PubMedCrossRefGoogle Scholar
  2. 2.
    Ruge MI, Kocher M, Maarouf M et al (2011) Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases. Strahlenther Onkol 187:7–14PubMedCrossRefGoogle Scholar
  3. 3.
    Runge M, Maarouf M, Hunsche S et al (2012) Linac radiosurgery for nonsecreting pituitary adenomas: long-term results. Strahlenther Onkol 188:319–327PubMedCrossRefGoogle Scholar
  4. 4.
    Becker G, Kocher M, Kortmann R et al (2002) Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol 178:173–186PubMedCrossRefGoogle Scholar
  5. 5.
    Minniti G, Amichetti M, Enrici RM (2009) Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncology 4:42CrossRefGoogle Scholar
  6. 6.
    Minniti G, Scaringi C, Enrici RM (2011) Radiation techniques for acromegaly. Radiat Oncology 6:167CrossRefGoogle Scholar
  7. 7.
    D’Agostino GR, Autorino R, Pompucci A et al (2011) Whole-brain radiotherapy combined with surgery or stereotactic radiotherapy in patients with brain oligometastases: long-term analysis. Strahlenther Onkol 187:421–425CrossRefGoogle Scholar
  8. 8.
    Balducci M, Apicella G, Manfrida S et al (2010) Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. Strahlenther Onkol 186:558–564PubMedCrossRefGoogle Scholar
  9. 9.
    Zwicker F, Hauswald H, Nill S et al (2010) New multileaf collimator with a leaf width of 5 mm improves plan quality compared to 10 mm in step-and-shoot IMRT of HNC using integrated boost procedure. Strahlenther Onkol 186:334–343PubMedCrossRefGoogle Scholar
  10. 10.
    Milker-Zabel S, Huber P, Schlegel W et al (2009) Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas. J Neurooncol 94:419–424PubMedCrossRefGoogle Scholar
  11. 11.
    Minniti G, Traish D, Ashley S et al (2006) Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas. Clin Endocrinol 64:542–548CrossRefGoogle Scholar
  12. 12.
    Saeed P, Blank L, Selva D et al (2010) Primary radiotherapy in progressive optic nerve sheath meningiomas: a long term follow-up study. Br J Ophthalmol 94:564–568PubMedCrossRefGoogle Scholar
  13. 13.
    Baumert BG, Villa S, Studer G et al (2004) Early improvements in vision after fractionated stereotactic radiotherapy for primary optic nerve sheath meningioma. Radiother Oncol 72:169–174PubMedCrossRefGoogle Scholar
  14. 14.
    Landert M, Baumert BG, Bosch M et al (2005) The visual impact of fractionated stereotactic conformal radiotherapy on seven eyes with optic nerve sheath meningeomas. J neuro-Ophthalmol 25:86–91Google Scholar
  15. 15.
    Stiebel-Kalish H, Reich E, Gal L et al (2012) Visual outcome in meningiomas around anterior visual pathways treated with linear accelerator fractionated stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 82:779–788PubMedCrossRefGoogle Scholar
  16. 16.
    Paulsen F, Doerr S, Wilhelm H et al (2012) Fractionated stereotactic radiotherapy in patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys 82:773–778PubMedCrossRefGoogle Scholar
  17. 17.
    Adeberg S, Welzel T, Rieken S et al (2011) Prior surgical intervention and tumor size impact clinical outcome after precision radiotherapy for the treatment of optic nerve sheath meningiomas (ONSM). Radiat Oncology 6:117CrossRefGoogle Scholar
  18. 18.
    Arvold ND, Lessell S, Bussiere M et al (2009) Visual outcome and tumor control after conformal radiotherapy for patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys 75:1166–1172PubMedCrossRefGoogle Scholar
  19. 19.
    Jeremic B, Pitz S (2007) Primary optic nerve sheath meningeoma. Cancer 110:714–722PubMedCrossRefGoogle Scholar
  20. 20.
    Combs SE, Schulz-Ertner D, Moschos D et al (2005) Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys 62:814–819PubMedCrossRefGoogle Scholar
  21. 21.
    Kanesaka N, Mikami R, Nakayama H et al (2012) Preliminary results of fractionated stereotactic radiotherapy after cyst drainage for craniopharyngioma in adults. Int J Radiat Oncol Biol Phys 82:1356–1360PubMedCrossRefGoogle Scholar
  22. 22.
    Combs SE, Thilmann C, Huber PE et al (2007) Achievement of long-term local control in patients with craniopharyngeomas using high precision stereotactic radiotherapy. Cancer 109:2308–2314PubMedCrossRefGoogle Scholar
  23. 23.
    Lo SS, Fakiris AJ, Henderson MA et al (2008) Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy in pediatric brain tumors. Expert Rev Neurotherapeutics 8:121–132CrossRefGoogle Scholar
  24. 24.
    Minniti G, Saran F, Traish D et al (2007) Fractionated stereotactic conformal radiotherapy following conservative surgery in the control of craniopharyngiomas. Radiother Oncol 82:90–95PubMedCrossRefGoogle Scholar
  25. 25.
    Minniti G, Esposito V, Amichetti M, Maurizi Enrici R (2009) The role of fractionated radiotherapy and radiosurgery in the management of patients with craniopharyngeoma. Neurosurg Rev 32:125–132PubMedCrossRefGoogle Scholar
  26. 26.
    Elhateer H, Muanza T, Roberge D et al (2008) Fractionated stereotactic radiotherapy in the treatment of pituitary macroadenomas. Curr Oncol 15:286–292PubMedGoogle Scholar
  27. 27.
    Roug S, Rasmussen AK, Juhler M et al (2010) Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit. Europ J Endocrinol 162:685–694CrossRefGoogle Scholar
  28. 28.
    Colin P, Jovenin N, Delemer B et al (2005) Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat Oncol Biol Phys 62:333–341PubMedCrossRefGoogle Scholar
  29. 29.
    Schalin-Jaentti C, Valannet L, Tenhunen M et al (2010) Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study. Clin Endocrinol 73:72–77Google Scholar
  30. 30.
    Paek SH, Downes MB, Bednarz G et al (2005) Integration of surgery with fractionated stereotactic radiotherapy for treatment of nonfunctioning pituitary macroadenomas. Int J Radiat Oncol Biol Phys 61:795–808PubMedCrossRefGoogle Scholar
  31. 31.
    Minniti G, Clarke E, Cavallo L et al (2011) Fractionated stereotactic conformal radiotherapy for large benign skull base meningeomas. Radiat Oncology 6:36CrossRefGoogle Scholar
  32. 32.
    Onodera S, Aoyama H, Katoh N et al (2011) Long-term outcome of fractionated stereotactic radiotherapy for intracranial skull base meningiomas in single institution. Jpn J Clin Oncol 41:462–468PubMedCrossRefGoogle Scholar
  33. 33.
    Behbehani RS, McElveen T, Sergott RC et al (2005) Fractionated stereotactic radiotherapy for parasellar meningeomas: a preliminary report of visual outcomes. Br J Ophthalmol 89:130–133PubMedCrossRefGoogle Scholar
  34. 34.
    Milker-Zabel S, Zabel-du Bois A, Huber P et al (2006) Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas. Strahlenther Onkol 182:635–640PubMedCrossRefGoogle Scholar
  35. 35.
    Selch M, Ahn E, Laskari A et al (2004) Stereotactic radiotherapy for treatment of cavernous sinus meningeomas. Int J Radiat Oncol Biol Phys 59:101–111PubMedCrossRefGoogle Scholar
  36. 36.
    Brell M, Villa S, Teixidor P et al (2006) Fractionated stereotactic radiotherapy in the treatment of exclusive cavernous sinus meningioma: functional outcome, local control, and tolerance. Surg Neurol 65:28–34PubMedCrossRefGoogle Scholar
  37. 37.
    Litre CF, Colin P, Noudel R et al (2009) Fractionated stereotactic radiotherapy treatment of cavernous sinus meningeomas: a study of 100 cases. Int J Radiat Oncol Biol Phys 74:1012–1017PubMedCrossRefGoogle Scholar
  38. 38.
    Trippa F, Maranzano E, Costantini S, Giorgi C (2009) Hypofractionated stereotactic radiotherapy for intracranial meningiomas: preliminary results of a feasibility trial. J Neurosurg 53:7–11Google Scholar
  39. 39.
    Astner ST, Theodorou M, Dobrei-Ciuchendea M et al (2010) Tumor shrinkage assessed by volumetric MRI in the long-term follow-up after strereotactic radiotherapy of meningiomas. Strahlenther Onkol 186:423–429PubMedCrossRefGoogle Scholar
  40. 40.
    Adler J, Gibbs I, Puataweepong P, Chang S (2006) Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions. Neurosurg 59:244–254CrossRefGoogle Scholar
  41. 41.
    Bria C, Wegner RE, Clump DA et al (2011) Fractionated stereotactic radiosurgery for the treatment of meningeomas. J Cancer Res Ther 7:52–57PubMedCrossRefGoogle Scholar
  42. 42.
    Iwata H, Sato K, Tatewaki K et al (2011) Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro Oncol 13Google Scholar
  43. 43.
    Kajiwara K, Saito K, Yoshikawa K et al (2005) Image-guided stereotactic radiosurgery with the CyberKnife for pituitary adenomas. Minim Invasive Neurosurg 48:91–96PubMedCrossRefGoogle Scholar
  44. 44.
    Killory B, Kresl J, Wait S et al (2009) Hypofractionated CyberKnife radiosurgery for perichiasmatic pituitary adenomas: early results. Neurosurg 64:A19–A25CrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  • M. Kocher
    • 1
  • H. Treuer
    • 2
  • M. Hoevels
    • 2
  • R. Semrau
    • 1
  • V. Sturm
    • 2
  • R.-P. Mueller
    • 1
  1. 1.Klinik und Poliklinik für StrahlentherapieUniKlinik KölnCologneDeutschland
  2. 2.Department of Stereotaxy and Functional NeurosurgeryUniversity of CologneCologneGermany

Personalised recommendations